{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:05:38Z","timestamp":1789776338631,"version":"4.0.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.diabet.2026.101793","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:31:15Z","timestamp":1789774275000},"page":"101793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative management of SGLT2 inhibitors: balancing euglycaemic ketoacidosis risk and cardiorenal benefits"],"prefix":"10.1016","author":[{"given":"Keqin","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2026.101793_bib0001","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101793_bib0002","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.diabet.2026.101793_bib0003","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101793_bib0004","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.2337\/dc26-S010","article-title":"Cardiovascular disease and risk management: Standards of Care in Diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101793_bib0005","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.2337\/dc26-S011","article-title":"11. Chronic kidney disease and risk management: Standards of Care in Diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101793_bib0006","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2026.101793_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/EJA.0000000000002069","article-title":"Preoperative assessment of adults undergoing elective noncardiac surgery: updated guidelines from the European Society of Anaesthesiology and Intensive Care","volume":"42","author":"Lamperti","year":"2025","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.diabet.2026.101793_bib0008","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1213\/ANE.0000000000006791","article-title":"Society for Ambulatory Anesthesia updated consensus statement on perioperative blood glucose management in adult patients with diabetes mellitus undergoing ambulatory surgery","volume":"139","author":"Rajan","year":"2024","journal-title":"Anesth Analg"},{"key":"10.1016\/j.diabet.2026.101793_bib0009","series-title":"Guideline for perioperative care for people with diabetes mellitus undergoing elective and emergency surgery","year":"2023"},{"key":"10.1016\/j.diabet.2026.101793_bib0010","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.2215\/CJN.17621120","article-title":"Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy","volume":"16","author":"Palmer","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2026.101793_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.diabet.2026.101793_bib0012","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.2337\/dc26-S016","article-title":"16. Diabetes care in the hospital: Standards of Care in Diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101793_bib0013","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabet.2026.101793_bib0014","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.123.065748","article-title":"Blinded withdrawal of long-term randomized treatment with empagliflozin or placebo in patients with heart failure","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2026.101793_bib0015","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/anae.16607","article-title":"Outcomes in patients with chronic heart failure undergoing non-cardiac surgery: a secondary analysis of the METREPAIR international cohort study","volume":"80","author":"Kirkopoulos","year":"2025","journal-title":"Anaesthesia"},{"key":"10.1016\/j.diabet.2026.101793_bib0016","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jamasurg.2019.2110","article-title":"Association between heart failure and postoperative mortality among patients undergoing ambulatory noncardiac surgery","volume":"154","author":"Lerman","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.diabet.2026.101793_bib0017","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101793_bib0018","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2026.101793_bib0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bja.2019.03.028","article-title":"Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review","volume":"123","author":"Thiruvenkatarajan","year":"2019","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.diabet.2026.101793_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2026.1777334","article-title":"The SGLT2 inhibitor checklist: a comprehensive review of perioperative and acute phase safety management","volume":"17","author":"Deng","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabet.2026.101793_bib0021","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00540-023-03174-8","article-title":"Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports","volume":"37","author":"Seki","year":"2023","journal-title":"J Anesth"},{"key":"10.1016\/j.diabet.2026.101793_bib0022","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.4239\/wjd.v14.i8.1314","article-title":"Sodium-glucose cotransporter-2 inhibitors induced euglycemic diabetic ketoacidosis: a meta-summary of case reports","volume":"14","author":"Juneja","year":"2023","journal-title":"World J Diabetes"},{"key":"10.1016\/j.diabet.2026.101793_bib0023","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00540-024-03335-3","article-title":"Incidence of sodium\u2013glucose cotransporter-2 inhibitor-associated perioperative ketoacidosis in surgical patients: a prospective cohort study","volume":"38","author":"Seki","year":"2024","journal-title":"J Anesth"},{"key":"10.1016\/j.diabet.2026.101793_bib0024","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.eprac.2022.06.006","article-title":"Inpatient perioperative euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter-2 inhibitors: lessons from a case series and strategies to decrease incidence","volume":"28","author":"Mehta","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabet.2026.101793_bib0025","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s00540-025-03570-2","article-title":"Sodium glucose co-transporter 2 inhibitor-associated euglycaemic diabetic ketoacidosis in the emergency peri-operative period: a systematic review","volume":"39","author":"Perez Castillo","year":"2025","journal-title":"J Anesth"},{"key":"10.1016\/j.diabet.2026.101793_bib0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40264-022-01247-3","article-title":"A population-based study of SGLT2 inhibitor-associated postoperative diabetic ketoacidosis in patients with type 2 diabetes","volume":"46","author":"Lui","year":"2023","journal-title":"Drug Saf"},{"key":"10.1016\/j.diabet.2026.101793_bib0027","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.bja.2023.06.063","article-title":"Dose-dependent relationship between SGLT2 inhibitor hold time and risk for postoperative anion gap acidosis: a single-centre retrospective analysis","volume":"131","author":"Steinhorn","year":"2023","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.diabet.2026.101793_bib0028","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study","volume":"173","author":"Douros","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2026.101793_bib0029","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/metabo14050264","article-title":"Ketoacidosis and SGLT2 inhibitors: a narrative review","volume":"14","author":"Morace","year":"2024","journal-title":"Metabolites"},{"key":"10.1016\/j.diabet.2026.101793_bib0030","doi-asserted-by":"crossref","first-page":"m4147","DOI":"10.1136\/bmj.m4147","article-title":"Diabetic ketoacidosis with SGLT2 inhibitors","volume":"371","author":"Musso","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2026.101793_bib0031","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40780-025-00487-6","article-title":"Factors and preventive strategies for perioperative euglycemic diabetic ketoacidosis in patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors: a retrospective study","volume":"11","author":"Takemura","year":"2025","journal-title":"J Pharm Health Care Sci"},{"key":"10.1016\/j.diabet.2026.101793_bib0032","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.jvca.2023.10.011","article-title":"Perioperative management of patients receiving sodium-glucose cotransporter 2 inhibitors: development of a clinical guideline at a large academic medical center","volume":"38","author":"Raiten","year":"2024","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.diabet.2026.101793_bib0033","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.bja.2026.02.031","article-title":"Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement","volume":"136","author":"Oprea","year":"2026","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.diabet.2026.101793_bib0034","first-page":"16","article-title":"Guideline for the prevention and treatment of diabetes mellitus in China (2024 edition) [in Chinese]","volume":"17","year":"2025","journal-title":"Chin J Diabetes Mellitus"},{"key":"10.1016\/j.diabet.2026.101793_bib0035","series-title":"Peri-Procedure Management of Patients on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors","year":"2025"},{"key":"10.1016\/j.diabet.2026.101793_bib0036","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.mayocp.2020.10.002","article-title":"Preoperative Management of endocrine, hormonal, and urologic medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) consensus statement","volume":"96","author":"Pfeifer","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.diabet.2026.101793_bib0037","series-title":"Silver Spring","article-title":"FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections","year":"2022"},{"key":"10.1016\/j.diabet.2026.101793_bib0038","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/anae.16541","article-title":"Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement","volume":"80","author":"El-Boghdadly","year":"2025","journal-title":"Anaesthesia"},{"key":"10.1016\/j.diabet.2026.101793_bib0039","series-title":"Periprocedural Diabetic Ketoacidosis (DKA) with SGLT2 inhibitor use in people with diabetes: alert update","year":"2023"},{"key":"10.1016\/j.diabet.2026.101793_bib0040","series-title":"Type 2 Diabetes Focused Update: SGLT2 Inhibitors and GLP1 Agonists","year":"2023"},{"key":"10.1016\/j.diabet.2026.101793_bib0041","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1253\/circj.CJ-23-0605","article-title":"Recommendation for Appropriate Use of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure","volume":"87","author":"Tanaka","year":"2023","journal-title":"Circ J"},{"key":"10.1016\/j.diabet.2026.101793_bib0042","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2026.101793_bib0043","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2026.101793_bib0044","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101793_bib0045","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2026.101793_bib0046","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bja.2024.05.004","article-title":"Risk of perioperative discontinuation of SGLT2 inhibitors","volume":"133","author":"Oosterom-Eijmael","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.diabet.2026.101793_bib0047","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1161\/CIR.0000000000001285","article-title":"2024 AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"150","author":"Thompson","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2026.101793_bib0048","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2026.101793_bib0049","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101793_bib0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101793_bib0051","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium-glucose cotransporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2026.101793_bib0052","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.diabet.2026.101793_bib0053","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose cotransporter 2 inhibitors","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.diabet.2026.101793_bib0054","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101793_bib0055","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101793_bib0056","doi-asserted-by":"crossref","first-page":"ehag249","DOI":"10.1093\/eurheartj\/ehag249","article-title":"Perioperative dapagliflozin in diabetic patients undergoing cardiac surgery: the DAPA-CS trial","author":"Li","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2026.101793_bib0057","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamasurg.2025.0940","article-title":"Postoperative outcomes among sodium-glucose cotransporter 2 inhibitor users","volume":"160","author":"Tallarico","year":"2025","journal-title":"JAMA Surg"},{"key":"10.1016\/j.diabet.2026.101793_bib0058","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2026.101793_bib0059","article-title":"Perioperative prevention of euglycaemic diabetic ketoacidosis in people living with type 2 diabetes established on sodium-glucose transport-2 inhibitors: a cross-site multi-cycle audit","volume":"25","author":"Romain","year":"2025","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.diabet.2026.101793_bib0060","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/03007995.2025.2458538","article-title":"Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms","volume":"41","author":"Goldenberg","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabet.2026.101793_bib0061","series-title":"Perioperative management of patients on SGLT-2 inhibitors","author":"Iyengar","year":"2024"},{"key":"10.1016\/j.diabet.2026.101793_bib0062","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2337\/dci24-0032","article-title":"Hyperglycemic crises in adults with diabetes: a consensus report","volume":"47","author":"Umpierrez","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101793_bib0063","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14788","article-title":"Joint British Diabetes Societies for Inpatient Care. The management of diabetic ketoacidosis in adults: an updated guideline from the Joint British Diabetes Society for Inpatient Care","volume":"39","author":"Dhatariya","year":"2022","journal-title":"Diabet Med"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:31:22Z","timestamp":1789774282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363626000728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"alternative-id":["S1262363626000728"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101793","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative management of SGLT2 inhibitors: balancing euglycaemic ketoacidosis risk and cardiorenal benefits","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101793"}}